Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (Nasdaq: CTKB) has announced the acquisition of the cell analysis business from Tonbo Biosciences. This acquisition expands Cytek's portfolio with life science research reagents related to cell preparation, molecular immunology, and flow cytometry. The integration of Tonbo’s reagents into Cytek's existing offerings aims to enhance its flow cytometry capabilities, particularly in protein and cell analysis. This strategic move reflects Cytek's commitment to delivering comprehensive solutions in the cell analysis market.
Cytek Biosciences (Nasdaq: CTKB) announced it will release its third-quarter 2021 financial results on November 8, 2021, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook. Cytek is recognized for its innovation in cell analysis technologies, specifically its Full Spectrum Profiling™ (FSP™) platform, which supports advanced cellular analysis through high-resolution and high-sensitivity tools. The company's offerings include the Aurora and Northern Lights systems, with products primarily for research use, except for limited clinical applications in China and the EU.
Cytek Biosciences (Nasdaq: CTKB) launched a new 25-color immunoprofiling assay optimized for the Aurora full spectrum flow cytometer. This assay simplifies workflows from sample preparation to data analysis, aiding in immunology research for vaccines and therapies. It identifies key immune cell populations and is complemented by an 18-color cFluor reagent kit. Dr. Wenbin Jiang emphasized the company's commitment to accelerating immunology discoveries. The assay features user-friendly protocols to enhance laboratory efficiency, advancing research on T, B, NK cells, and more.
Cytek Biosciences announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. PT. Interested parties can access the live and archived webcast through the company's Investors section of their website.
Cytek specializes in cell analysis solutions, utilizing its proprietary Full Spectrum Profiling™ (FSP™) technology for highly sensitive and multiplexed cell analysis. Their core products include the Aurora and Northern Lights™ systems, and they operate globally from their headquarters in Fremont, California.
Cytek Biosciences (Nasdaq: CTKB) reported a strong second quarter for 2021, achieving total revenue of $30.4 million, a 59% increase from Q2 2020. The company expanded its installed base to 855 instruments, adding 104 placements during the quarter. Gross profit surged by 137% to $19.7 million, with a 65% gross profit margin. Operating expenses rose by 87% to $15.9 million, mainly due to product development and increased headcount. Despite these expenses, net income stood at $2.7 million for Q2 2021, down from $8.1 million in the previous year.
Cytek Biosciences, a leader in cell analysis solutions, announced that underwriters fully exercised their option to purchase an additional 2,184,695 shares at $17.00 per share. This brings the total shares sold in its recent IPO to 16,749,330, generating $237 million in gross proceeds before expenses. The IPO, completed on July 27, 2021, included shares sold by both Cytek and certain stockholders. Joint book-running managers for the offering were Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen.
Cytek Biosciences announced the closing of its initial public offering, raising $200 million by selling 14,564,635 shares at $17.00 per share. The offering included 11,764,706 shares from Cytek and 2,799,929 shares from selling stockholders. Cytek did not receive proceeds from the latter. Additionally, underwriters were granted a 30-day option to purchase 2,184,695 shares to cover over-allotments. Shares are traded on Nasdaq under the symbol CTKB.